The success of copyright’s blockbuster initially drove a boom for pharma, but recent shifts present a complicated outlook for those considering a stake. Lower-cost alternatives are eating into revenue, and continued https://nicolasefoh293169.ka-blogs.com/94657733/the-blue-pill-and-big-pharma-a-risky-investment